fool.com · 8 jul

2 Fast-Growing Pharmaceutical Stocks to Buy Now

Incyte and TG Therapeutics are seeing strong share growth, backed up by booming revenue and earnings.

businesswire.com · 8 jul

Incyte to Report Second Quarter Financial Results

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) announced today that it has scheduled its second quarter financial results conference call and webcast for 8:00 a.m. ET on Tuesday, July 28, 2026. The schedule for the press release and conference call/webcast is as follows: Q2 2026 Press Release: July 28, 2026, at 7:00 a.m. ET Q2 2026 Conference Call: July 28, 2026, at 8:00 a.m. ET Domestic Dial-In Number: 877-407-3042 International Dial-In Number: 201-389-0864 Conference ID Number: 13759.

businesswire.com · 6 jul

Incyte Completes Acquisition of Vega Therapeutics, a Wholly Owned Subsidiary of Star Therapeutics, Expanding its Hematology Portfolio

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Completes Acquisition of Vega Therapeutics, a Wholly Owned Subsidiary of Star Therapeutics, Expanding its Hematology Portfolio.

fxempire.com · 3 jul

Incyte Shares Rise on EPS Growth, Lifted Guidance, Expansion

Three outlier inflow signals push biopharmaceutical firm Incyte Corporation (INCY) up 71% in a year.

zacks.com · 29 jun

INCY Stock Hits 52-Week High on Regulatory Updates for Opzelura

Incyte shares hit a 52-week high as Opzelura gains regulatory momentum, pipeline advances and a CMS settlement boosts investor sentiment.

zacks.com · 29 jun

Incyte (INCY) Surges 5.8%: Is This an Indication of Further Gains?

Incyte (INCY) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

seekingalpha.com · 29 jun

Incyte: New Catalysts Support Another Leg Higher

Incyte Corporation remains a strong long pick, with a maintained 'Buy' rating and a 40% upside to a $159.5/share price target. Recent catalysts include a positive CHMP opinion for Opzelura in Europe and the acquisition of Vega Therapeutics, expanding INCY's product portfolio and reducing Jakafi concentration risk. Q1 2026 results showed robust diversification: revenues up 21% YoY, adjusted EPS up 56% YoY, and ex-Jakafi sales up 63% YoY.

gurufocus.com · 26 jun

Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis

Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positi